No Data
Johnson & Johnson's (JNJ.US) combination therapy for cancer is expected to be approved in the EU for the treatment of multiple myeloma.
Johnson & Johnson recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the extension of the indications for the subcutaneous (SC) formulation of Darzalex (daratumumab).
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD) and Genmab (GMAB)
6-K: Report of foreign private issuer (related to financial reporting)
Top Gap Ups and Downs on Tuesday: LI, PHG, MSTR and More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
